India's Panacea Biotec to make up to 25 million doses of Sputnik V vaccine
05/08/2021 10:52
BENGALURU, Aug 5 (Reuters) - India's Panacea Biotec Ltd
PNCA.NS said on Thursday it had agreed to produce up to 25
million doses of the Sputnik V COVID-19 vaccine using the drug
substance made by Russia's Generium.
Panacea will then supply the doses to drugmaker Dr. Reddy's
Laboratories REDY.NS for distribution in India. (https://bit.ly/3joeloz)
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by
Shailesh Kuber)
((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))
Recent news on Panacea Biotec
See all newsBrief: Panacea Biotec Receives Letter Of Award For BOPV Supply Worth $8.205 Million
Brief: Panacea Biotec Unit Gets Show Cause Notice Alleging Total Tax Liability Of 40.6 Million Rupees
Brief: Panacea Biotec Files Appeal Against Fourth Industrial Tribunal (Mohali) Award
India's Panacea Biotec rises to record high on EU-backed dengue vaccine project
India Stocks: Indian shares rise as banks gain on RBI forex swap facility